J&J starts Phase III of Tremfya in plaque-type psoriasis

MorphoSys AG (Xetra:MOR; Pink:MPSYY) said the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) began the Phase III ECLIPSE trial to compare Tremfya guselkumab (CNTO 1959) to Cosentyx secukinumab for 44 weeks in about 1,040 patients with moderate to severe plaque-type psoriasis.

The primary endpoint of the double-blind, international trial is the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) 90 response at week 48. Secondary endpoints include PASI90 response rate at week 12, PASI75 response rate at week 12, PASI75 response rate at both week 12 and 48, PASI100 response rate at week 48 and number of patients graded as cleared by Investigator’s Global Assessment (IGA) score at week 48...